# Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

> **NCT00871117** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 478 (actual)

## Conditions studied

- Tetanus
- Acellular Pertussis
- Diphtheria

## Interventions

- **BIOLOGICAL:** GSK Biologicals'Kinrix®
- **BIOLOGICAL:** Merck and Company's MMRII
- **BIOLOGICAL:** Merck and Company's Varivax

## Key facts

- **NCT ID:** NCT00871117
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-31
- **Primary completion:** 2010-01-15
- **Final completion:** 2010-06-15
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00871117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00871117, "Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00871117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*